Glycolytic enzyme inhibitors affect pancreatic cancer survival by modulating its signaling and energetics

Anticancer Research

Volumn 30, Issue 3, 2010, Pages 743-749

  Bhardwaj, Vikas ^a   Rizvi, Nisha ^a   Lai, Maria B ^a   Lai, James C K ^a   Bhushan, Alok ^a  

^a IDAHO STATE UNIVERSITY   (United States)

Author keywords

Glycolytic inhibitors; Pancreatic cancer; Signaling

Indexed keywords

BROMOPYRUVIC ACID; ENZYME INHIBITOR; GLYCOLYTIC ENZYME; GLYCOLYTIC ENZYME INHIBITOR; HEXOKINASE; IODOACETIC ACID; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL DEATH; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; CONCENTRATION RESPONSE; ENERGY TRANSFER; ENZYME INHIBITION; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASES; GLYCOLYSIS; HEXOKINASE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; IODOACETATES; MITOGEN-ACTIVATED PROTEIN KINASE 3; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRUVATES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 77951075491     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. American Cancer Society. Cancer Facts and Figures 2007. Atlanta: American Cancer Society, 2007.
2. Patrick SM, Stefania B, Zamboni G and Scarpa A: Genetic abnormalities in pancreatic cancer. Mol Cancer 7: 2-7, 2003.
3. American Cancer Society. Cancer Facts and Figures 2008. Atlanta: American Cancer Society, 2008.
4. Rosenberg L: Pancreatic cancer. A review of emerging therapies. Drugs 59(5): 1071-1089, 2000.
5. Zalatnai A: Pancreatic cancer - a continuing challenge in oncology: Pathol Oncol Research 9(4): 252-263, 2003.
6. Pour PM, Pandey KK and Batra SK: What is the origin of pancreatic carcinoma? Mol Cancer 22: 2-13, 2003.
7. Hruban RH, Christine Iacobuzio-Donahue C, Wilentz RE, Goggins M and Kern SE: Molecular pathology of pancreatic cancer. Cancer J 7(4): 251-258, 2001.
8. Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N and Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 20(10): 1218-1249, 2006.
9. Ghaneh P, Kawesha A, Evans JD and Neoptolemos JP: Molecular prognostic markers in pancreatic cancer. J Hepatobiliary Pancreat Surg 9(1): 1-11, 2002.
10. Talapatra S and Thompson CB: Growth factor signaling in cell survival: implications for cancer treatment: J Pharmcol Exp Ther 298(3): 873-878, 2001.
11. Jung-wham Kim and Dang CV: Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66(18): 8927-8930, 2006.
12. Semenza GL, Artemov D, Bedi A, Bhujwalla Z, Chiles K, Feldser D, Laughner E, Ravi R, Simons J, Taghavi P and Zhong H: 'The metabolism of tumours': 70 years later. Novartis Found Symp 240: 251-260, 2001.
13. Pelicano H, Martin DS, Xu R-H and Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 25(34): 4633-4646, 2006.
14. Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM and Thompson CB: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 64(11): 3892-3899, 2004.
15. Robey IF, Lien AD, Welsh SJ, Baggett BK and Gillies RJ: Hypoxia-inducible factor 1alpha and the glycolytic phenotype in tumors. Neoplasia 7(4): 324-330, 2005.
16. Jung-wham Kim and Dang CV: Multifaceted roles of glycolytic enzymes. Trends Biochem Sci 30(3): 142-150, 2005.
17. Puli S, Lai JCK, Edgley KL, Daniels CK and Bhushan A: Signaling pathways mediating manganese-induced toxicity in human glioblastoma cells (U87). Neurochem Res 31(10): 1211-1218, 2006.
18. Clark JB and Lai JCK: Glycolytic, tricarboxylic acid cycle, and related enzymes in brain. In: NeuroMethods 11. Boulton AA, Baker GB and Butterworth RF (eds.). New Jersey, Humana Press, pp. 233-281, 1989.
19. Pedersen PL: Warburg, me and hexokinase 2: Multiple discoveries of key molecular events underlying one of the cancers' most common phenotypes, the 'Warburg Effect', i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 39: 211-222, 2007.
20. Ko YH, Pedersen PL and Geschwind JF: Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173(1): 83-91, 2001.
21. Geschwind JF, Ko YH, Torbenson MS, Magee C and Pedersen PL: Novel therapy for liver cancer: direct intra-arterial injection of a potent inhibitor of ATP production. Cancer Res 62(14): 3909-3913, 2002.
22. Mikuriya K, Kuramitsu Y, Ryozawa S, Fujimoto M, Mori S, Oka M, Hamano K, Okita K, Sakaida I and Nakamura K: Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/ mass spectrometry. Int J Oncol 30(4): 849-855, 2007.
23. Schek N, Hall BL and Finn OJ: Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma. Cancer Res 48(22): 6354-6359, 1998.
24. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ and Huang P: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65(2): 613-621, 2005.